Compare CWD & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CWD | OSRH |
|---|---|---|
| Founded | 2009 | N/A |
| Country | United States | United States |
| Employees | N/A | 21 |
| Industry | Real Estate | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 11.4M |
| IPO Year | 2022 | N/A |
| Metric | CWD | OSRH |
|---|---|---|
| Price | $1.15 | $0.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 36.4K | ★ 337.8K |
| Earning Date | 03-25-2026 | 04-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $51,119,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $26.79 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.20 | $0.38 |
| 52 Week High | $46.21 | $4.33 |
| Indicator | CWD | OSRH |
|---|---|---|
| Relative Strength Index (RSI) | 39.11 | 38.62 |
| Support Level | $1.11 | $0.39 |
| Resistance Level | $1.55 | $0.47 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 12.69 | 14.95 |
CaliberCos Inc is an asset management firm whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. The majority of revenue is derived from the fund management fees segment.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.